Wordt geladen...
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
BACKGROUND: The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events. METHODS: Event rates...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2009
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2688482/ https://ncbi.nlm.nih.gov/pubmed/19416529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1478-7547-7-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|